Massimo Broggini

List of Publications by Year
in descending order

203	6,557	66234	82410
papers	citations	42 h-index	72 g-index

210	210	210	9625
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncology, The, 2013, 14, 981-988.	5.1	472
2	Epithelialâ€“mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact. Cancer Treatment Reviews, 2012, 38, 689-697.	3.4	235
3	Platinum Resistance in Ovarian Cancer: Role of DNA Repair. Cancers, 2019, 11, 119.	1.7	196
4	Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 6780-6784.	3.3	186
5	Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Annals of Oncology, 2011, 22, 235-237.	0.6	170
6	Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney International, 1986, 30, 488-496.	2.6	158
7	Oct-4 Expression in Adult Human Differentiated Cells Challenges Its Role as a Pure Stem Cell Marker. Stem Cells, 2007, 25, 1675-1680.	1.4	151
8	Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia, 2003, 17, 52-59.	3.3	142
9	Phospholipase Cî³1 Is Required for Metastasis Development and Progression. Cancer Research, 2008, 68, 10187-10196.	0.4	135
10	PRL-3 Phosphatase Is Implicated in Ovarian Cancer Growth. Clinical Cancer Research, 2005, 11, 6835-6839.	3.2	134
11	Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway by Inositol Pentakisphosphate Results in Antiangiogenic and Antitumor Effects. Cancer Research, 2005, 65, 8339-8349.	0.4	126
12	Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53. Nucleic Acids Research, 2007, 35, 2093-2104.	6.5	123
13	Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle, 2012, 11, 2507-2517.	1.3	110
14	Distamycins inhibit the binding of OTF-1 and NFE-1 transfactors to their conserved DNA elements. Nucleic Acids Research, 1989, 17, 1051-1059.	6.5	99
15	DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. Nucleic Acids Research, 1995, 23, 81-87.	6.5	92
16	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. Clinical Cancer Research, 2018, 24, 120-129.	3.2	92
17	Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. Oncogene, 2004, 23, 1754-1765.	2.6	89
18	Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and Î²-catenin/Wnt pathways. European Journal of Cancer, 2010, 46, 1679-1691.	1.3	85

#	Article	IF	Citations
19	p53 Regulates the Minimal Promoter of the Human Topoisomerase IIÂ Gene. Nucleic Acids Research, 1996, 24, 4464-4470.	6.5	83
20	CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. , 1999, 26, 176-180.		82
21	Inactivation of p53 in a Human Ovarian Cancer Cell Line Increases the Sensitivity to Paclitaxel by Inducing G2/M Arrest and Apoptosis. Experimental Cell Research, 1998, 241, 96-101.	1.2	81
22	Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells. Oncotarget, 2014, 5, 4722-4731.	0.8	80
23	Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. Journal of Thoracic Oncology, 2018, 13, 1692-1704.	0.5	74
24	Novel functional PI 3â€kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines. FASEB Journal, 2000, 14, 1179-1187.	0.2	73
25	Cisplatinum and Taxol Induce Different Patterns of p53 Phosphorylation. Neoplasia, 2001, 3, 10-16.	2.3	73
26	Chk1, but not Chk2 , is Involved in the Cellular Response to DNA Damaging Agents: Differential Activity in Cells Expressing, or not, p53. Cell Cycle, 2004, 3, 1175-1179.	1.3	68
27	Combination of PI3K/mTOR Inhibitors: Antitumor Activity and Molecular Correlates. Cancer Research, 2011, 71, 4573-4584.	0.4	68
28	KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. Oncotarget, 2015, 6, 34014-34022.	0.8	68
29	Spectrum of Cellular Responses to Pyriplatin, a Monofunctional Cationic Antineoplastic Platinum(II) Compound, in Human Cancer Cells. Molecular Cancer Therapeutics, 2011, 10, 1709-1719.	1.9	67
30	Breast Cancerâ€"Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown. Molecular Cancer Therapeutics, 2012, 11, 214-223.	1.9	58
31	Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer Drugs. Clinical Cancer Research, 2005, 11, 4348-4356.	3.2	57
32	Preliminary safety evaluation of the putative cancer chemopreventive agent tricin, a naturally occurring flavone. Cancer Chemotherapy and Pharmacology, 2006, 57, 1-6.	1.1	57
33	Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer. Oncogene, 2008, 27, 1805-1811.	2.6	54
34	Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts. Gynecologic Oncology, 2010, 118, 182-188.	0.6	54
35	A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. British Journal of Cancer, 2010, 102, 104-114.	2.9	54
36	RAS/RAF/MEK Inhibitors in Oncology. Current Medicinal Chemistry, 2012, 19, 1164-1176.	1.2	54

#	Article	IF	Citations
37	Expression of Genes of Potential Importance in the Response to Chemotherapy and DNA Repair in Patients with Ovarian Cancer. Gynecologic Oncology, 1997, 65, 130-137.	0.6	53
38	Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Research, 1994, 22, 1012-1017.	6.5	52
39	Effect of Aplidin in acute lymphoblastic leukaemia cells. British Journal of Cancer, 2003, 89, 763-773.	2.9	52
40	p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. Oncogene, 2001, 20, 7293-7300.	2.6	51
41	Î”Np63 expression is associated with poor survival in ovarian cancer. Annals of Oncology, 2008, 19, 501-507.	0.6	50
42	Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2. Cell Cycle, 2014, 13, 2296-2305.	1.3	48
43	Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer Research, 2002, 62, 2332-6.	0.4	45
44	Analysis of Gene Expression in Early-Stage Ovarian Cancer. Clinical Cancer Research, 2008, 14, 7850-7860.	3.2	43
45	Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype. Cell Cycle, 2012, 11, 1966-1976.	1.3	43
46	Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells. Oncotarget, 2015, 6, 30072-30087.	0.8	43
47	Checkpoint Kinase 1 Down-Regulation by an Inducible Small Interfering RNA Expression System Sensitized In vivo Tumors to Treatment with 5-Fluorouracil. Clinical Cancer Research, 2008, 14, 5131-5141.	3.2	42
48	Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. Annals of Oncology, 2015, 26, 2079-2084.	0.6	42
49	PI3K/AKT/mTOR Inhibitors In Ovarian Cancer. Current Medicinal Chemistry, 2010, 17, 4433-4447.	1.2	41
50	Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents. British Journal of Cancer, 1999, 80, 338-343.	2.9	39
51	Silver Ions as a Tool for Understanding Different Aspects of Copper Metabolism. Nutrients, 2019, 11, 1364.	1.7	38
52	p73: A chiaroscuro gene in cancer. European Journal of Cancer, 2007, 43, 1361-1372.	1.3	37
53	Development of distamycin-related DNA binding anticancer drugs. Expert Opinion on Investigational Drugs, 2001, 10, 1703-1714.	1.9	35
54	Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes. PLoS ONE, 2013, 8, e66243.	1.1	35

#	Article	IF	Citations
55	Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle, 2004, 3, 1177-81.	1.3	35
56	Down-regulation of the Nucleotide Excision Repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells. Molecular Cancer, 2010, 9, 259.	7.9	34
57	Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist. Annals of Oncology, 2013, 24, 14-20.	0.6	34
58	Brassinin and its derivatives as potential anticancer agents. Toxicology in Vitro, 2014, 28, 909-915.	1.1	31
59	Brostallicin: a new concept in minor groove DNA binder development. Anti-Cancer Drugs, 2004, 15, 1-6.	0.7	30
60	DNA damage induces transcriptional activation of p73 by removing C-EBPÂ repression on E2F1. Nucleic Acids Research, 2003, 31, 6624-6632.	6.5	29
61	Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo. Scientific Reports, 2016, 6, 28398.	1.6	29
62	Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. European Journal of Cancer, 2008, 44, 131-141.	1.3	28
63	Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Molecular Cancer Therapeutics, 2005, 4, 715-725.	1.9	27
64	HtrA2 enhances the apoptotic functions of p73 on bax. Cell Death and Differentiation, 2008, 15, 849-858.	5.0	27
65	Benzylidenetetralones, cyclic chalcone analogues, induce cell cycle arrest and apoptosis in HCT116 colorectal cancer cells. Tumor Biology, 2014, 35, 9967-9975.	0.8	27
66	Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach. Journal of Experimental and Clinical Cancer Research, 2018, 37, 302.	3.5	27
67	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. Journal of Experimental and Clinical Cancer Research, 2018, 37, 140.	3.5	27
68	Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. Clinical Lung Cancer, 2019, 20, e413-e417.	1.1	27
69	Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer. Current Pharmaceutical Design, 2014, 20, 3933-3943.	0.9	27
70	Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice. Cancer Chemotherapy and Pharmacology, 1982, 7, 127-31.	1.1	26
71	Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin. Epigenetics, 2013, 8, 656-665.	1.3	26
72	Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?. Cancer Treatment Reviews, 2016, 48, 8-19.	3.4	26

#	Article	IF	Citations
73	TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR.. Journal of Clinical Oncology, 2012, 30, LBA7501-LBA7501.	0.8	26
74	Improving the selectivity of cancer treatments by interfering with cell response pathways. European Journal of Cancer, 2004, 40, 2550-2559.	1.3	25
75	Class II phosphoinositide 3-kinase C2Î² regulates a novel signaling pathway involved in breast cancer progression. Oncotarget, 2016, 7, 18325-18345.	0.8	25
76	Revisiting ovarian cancer preclinical models: Implications for a better management of the disease. Cancer Treatment Reviews, 2013, 39, 561-568.	3.4	24
77	Direct but not indirect co-culture with osteogenically differentiated human bone marrow stromal cells increases RANKL/OPG ratio in human breast cancer cells generating bone metastases. Molecular Cancer, 2014, 13, 238.	7.9	24
78	LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors. Journal of Thoracic Oncology, 2020, 15, 360-370.	0.5	24
79	Structureâ€“Activity Relationships of Hexahydrocyclopenta[c]quinoline Derivatives as Allosteric Inhibitors of CDK2 and EGFR. ChemMedChem, 2018, 13, 2627-2634.	1.6	23
80	Characterization of the 5'flanking region of the human Chk1 gene: identification of E2F1 functional sites. Cell Cycle, 2003, 2, 604-9.	1.3	23
81	Intracellular doxorubicin concentrations and drug-induced DNA damage in a human colon adenocarcinoma cell line and in a drug-resistant subline. Biochemical Pharmacology, 1988, 37, 4423-4431.	2.0	22
82	Driving p53 Response to Bax Activation Greatly Enhances Sensitivity to Taxol by Inducing Massive Apoptosis. Neoplasia, 2000, 2, 202-207.	2.3	22
83	KCNA1 and TRPC6 ion channels and NHE1 exchanger operate the biological outcome of HGF/scatter factor in renal tubular cells. Growth Factors, 2007, 25, 382-391.	0.5	22
84	Preclinical Colorectal Cancer Chemopreventive Efficacy and p53-Modulating Activity of 3â€²,4â€²,5â€²-Trimethoxyflavonol, a Quercetin Analogue. Cancer Prevention Research, 2010, 3, 929-939.	0.7	22
85	The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer. Nature Communications, 2021, 12, 4651.	5.8	22
86	Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin. Clinical Cancer Research, 2003, 9, 5402-8.	3.2	22
87	Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: Possible role of p53. , 1997, 72, 155-159.		21
88	Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. Annals of Oncology, 2015, 26, 838-847.	0.6	21
89	Probing an Allosteric Pocket of CDK2 with Small Molecules. ChemMedChem, 2017, 12, 33-41.	1.6	21
90	Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking. Future Medicinal Chemistry, 2018, 10, 1545-1553.	1.1	21

#	Article	IF	Citations
91	Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS. Oncotarget, 2016, 7, 51462-51472.	0.8	21
92	Î±-Bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity. British Journal of Cancer, 1999, 80, 991-997.	2.9	20
93	Serum depletion of holo-ceruloplasmin induced by silver ions in vivo reduces uptake of cisplatin. Journal of Inorganic Biochemistry, 2012, 116, 88-96.	1.5	19
94	DRAGO (KIAA0247), a New DNA Damageâ€“Responsive, p53-Inducible Gene That Cooperates With p53 as Oncosuppressor. Journal of the National Cancer Institute, 2014, 106, dju053.	3.0	19
95	Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib. Scientific Reports, 2018, 8, 948.	1.6	19
96	Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation. Cells, 2020, 9, 1766.	1.8	19
97	Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse. European Journal of Cancer & Clinical Oncology, 1986, 22, 173-179.	0.9	18
98	Establishment of l1210 leukemia cells resistant to the distamycin-a derivative (FCE 24517): Characterization and cross-resistance studies. International Journal of Cancer, 1993, 53, 308-314.	2.3	18
99	Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin. British Journal of Cancer, 1995, 71, 505-511.	2.9	18
100	Effects of inducible overexpression of DNp73Î± on cancer cell growth and response to treatment in vitro and in vivo. Cell Death and Differentiation, 2005, 12, 805-814.	5.0	18
101	Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines. PLoS ONE, 2016, 11, e0145647.	1.1	18
102	DNA Damage Induces p53-dependent Down-regulation of hCHK1. Journal of Biological Chemistry, 2001, 276, 10641-10645.	1.6	17
103	Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma. Cancer Chemotherapy and Pharmacology, 1983, 10, 208-11.	1.1	16
104	Role of Glutathione Transferases in the Mechanism of Brostallicin Activation. Biochemistry, 2010, 49, 226-235.	1.2	16
105	DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer. Pharmacogenomics Journal, 2013, 13, 159-172.	0.9	16
106	Non-hepatic tumors change the activity of genes encoding copper trafficking proteins in the liver. Cancer Biology and Therapy, 2013, 14, 614-624.	1.5	16
107	Genetic markers for prediction of treatment outcomes in ovarian cancer. Pharmacogenomics Journal, 2014, 14, 401-410.	0.9	16
108	Combination of the c-Met Inhibitor Tivantinib and Zoledronic Acid Prevents Tumor Bone Engraftment and Inhibits Progression of Established Bone Metastases in a Breast Xenograft Model. PLoS ONE, 2013, 8, e79101.	1.1	16

#	Article	IF	Citations
109	DNA-topoisomerase I activity and content in epithelial ovarian cancer. Annals of Oncology, 1998, 9, 313-318.	0.6	15
110	Experimental switching of copper status in laboratory rodents. Journal of Trace Elements in Medicine and Biology, 2011, 25, 27-35.	1.5	15
111	Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts. Molecular Cancer, 2017, 16, 97.	7.9	15
112	RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. Clinical Lung Cancer, 2018, 19, e811-e814.	1.1	15
113	RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients. Oncogene, 2018, 37, 6463-6476.	2.6	15
114	Studies of the mode of action of antitumour triazenes and triazinesâ€"III. Metabolism studies on hexamethylmelamine. Biochemical Pharmacology, 1982, 31, 625-631.	2.0	14
115	Changes in Cyclins and Cyclin-Dependent Kinases Induced by DNA Damaging Agents in a Human Ovarian Cancer Cell Line Expressing Mutated or Wild-Type P53. Experimental Cell Research, 1996, 227, 380-385.	1.2	14
116	hMLH1 and hMSH2 expression and BAX frameshift mutations in ovarian cancer cell lines and tumors. Carcinogenesis, 1998, 19, 691-694.	1.3	14
117	Downregulation of class II phosphoinositide 3-kinase PI3K-C2Î² delays cell division and potentiates the effect of docetaxel on cancer cell growth. Journal of Experimental and Clinical Cancer Research, 2019, 38, 472.	3.5	14
118	Influence of tumor on adriamycin concentration in blood cells. Cancer Chemotherapy and Pharmacology, 1980, 4, 209-12.	1.1	13
119	Diferential adriamycinÂ® istribution to blood components. European Journal of Drug Metabolism and Pharmacokinetics, 1981, 6, 115-122.	0.6	13
120	Differential inhibition of the DNA binding of transcription factors NFxB and OTF-1 by nitrogen mustard and quinacrine mustard: transcriptional implications. Carcinogenesis, 1993, 14, 1963-1967.	1.3	13
121	Inhibition of the Lysophosphatidylinositol Transporter ABCC1 Reduces Prostate Cancer Cell Growth and Sensitizes to Chemotherapy. Cancers, 2020, 12, 2022.	1.7	13
122	TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.. Journal of Clinical Oncology, 2012, 30, LBA7501-LBA7501.	0.8	13
123	Allelic expression of p73 in human ovarian cancers. Annals of Oncology, 1999, 10, 949-953.	0.6	12
124	In vivo evaluation of the role of DNp73Î± protein in regulating the p53-dependent apoptotic pathway after treatment with cytotoxic drugs. International Journal of Cancer, 2007, 120, 506-513.	2.3	12
125	Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind METâ€"Letter. Clinical Cancer Research, 2013, 19, 4290-4290.	3.2	12
126	CRISP-R/Cas9 Mediated Deletion of Copper Transport Genes CTR1 and DMT1 in NSCLC Cell Line H1299. Biological and Pharmacological Consequences. Cells, 2019, 8, 322.	1.8	12

#	Article	IF	Citations
127	P53-independent caspase-mediated apoptosis in human leukaemic cells is induced by a DNA minor groove binder with antineoplastic activity. Apoptosis: an International Journal on Programmed Cell Death, 1999, 4, 39-45.	2.2	11
128	ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients. American Journal of Cancer Research, 2013, 3, 221-9.	1.4	11
129	Horseradish peroxidase/hydrogen peroxide-catalyzed oxidation of VP16-213. Identification of a new metabolite. Chemico-Biological Interactions, 1985, 55, 215-224.	1.7	10
130	L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives. British Journal of Cancer, 1994, 69, 315-319.	2.9	10
131	Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). Scientific Reports, 2015, 5, 16331.	1.6	10
132	Adriamycin distribution in plasma and blood cells of cancer patients with altered hematocrit. European Journal of Cancer & Clinical Oncology, 1981, 17, 1089-1096.	0.9	9
133	Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE) Tj ETQq1 1 0.784314 rgBT /Overlock	2.9	9
134	Questioning the oncogenic role of Î”Np73Î± in different cell lines expressingÂp53Âor not. Cancer Biology and Therapy, 2006, 5, 794-803.	1.5	9
135	Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX. Translational Oncology, 2016, 9, 458-465.	1.7	9
136	Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models. Translational Oncology, 2017, 10, 153-157.	1.7	9
137	LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stressâ€“Based Treatments. Journal of Thoracic Oncology, 2021, 16, 1298-1311.	0.5	9
138	Importance of the presence of necrosis in studying drug distribution within tumor tissue. European Journal of Drug Metabolism and Pharmacokinetics, 1977, 2, 63-67.	0.6	8
139	DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate). British Journal of Cancer, 1990, 61, 285-289.	2.9	8
140	Cis dichlorodiammine platinum induced DNA interstrand cross-links in primary cultures of human ovarian cancer. British Journal of Cancer, 1991, 64, 288-292.	2.9	8
141	Genetic alterations in ovarian cancer cells that might account for sensitivity to chemotherapy in patients. International Review of Cytology, 2002, 219, 157-198.	6.2	8
142	Anti-Influenza Effect of Nanosilver in a Mouse Model. Vaccines, 2020, 8, 679.	2.1	8
143	In vivo studies with the novel anticancer agent mitozolomide (NSC 353451) on Lewis lung carcinoma. Cancer Chemotherapy and Pharmacology, 1986, 16, 125-8.	1.1	7
144	In vivo effect of copper status on cisplatin-induced nephrotoxicity. BioMetals, 2016, 29, 841-849.	1.8	7

#	Article	IF	Citations
145	Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells. BMC Cancer, 2018, 18, 1028.	1.1	7
146	KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer. American Journal of Cancer Research, 2012, 2, 298-308.	1.4	7
147	LKB1: Can We Target an Hidden Target? Focus on NSCLC. Frontiers in Oncology, 2022, 12, .	1.3	7
148	Role of Chk1 in the differentiation program of hematopoietic stem cells. Cellular and Molecular Life Sciences, 2010, 67, 1713-1722.	2.4	6
149	The Crossroads between Host Copper Metabolism and Influenza Infection. International Journal of Molecular Sciences, 2021, 22, 5498.	1.8	6
150	Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations. Frontiers in Oncology, 2020, 10, 532292.	1.3	6
151	Routes of elimination of hexamethylmelamine and pentamethylmelamine in the rat. Xenobiotica, 1982, 12, 315-321.	0.5	5
152	Subcellular distribution of adriamycin in the liver and tumor of 3LL-bearing mice. European Journal of Cancer & Clinical Oncology, 1983, 19, 419-426.	0.9	5
153	Characterization of a protein recognizing minor groove binders-damaged DNA. Nucleic Acids Research, 1996, 24, 4227-4233.	6.5	5
154	G48A, a New KRAS Mutation Found in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 1170-1175.	0.5	5
155	Establishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients. Cancers, 2020, 12, 3846.	1.7	5
156	New Omics Information for Clinical Trial Utility in the Primary Setting. Journal of the National Cancer Institute Monographs, 2011, 2011, 128-133.	0.9	4
157	Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer. Cancer Management and Research, 2013, 5, 15.	0.9	4
158	Early DNA damage induced in cells exposed to N10-propargyl 5,8-dideazafolic acid (CB 3717) or methotrexate. Biochemical Pharmacology, 1988, 37, 1875-1876.	2.0	3
159	To Target or Not to Target, That Is the Question. Journal of Clinical Oncology, 2013, 31, 1254-1254.	0.8	3
160	Germ Cell Tumors Overexpress the Candidate Therapeutic target Cyclin B1 Independently of p53 function. International Journal of Biological Markers, 2015, 30, 275-281.	0.7	3
161	EGFR mutations and EGFR tyrosine kinase inhibitors. Lancet Oncology, The, 2015, 16, 746-748.	5.1	3
162	The 5â€²UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs. Scientific Reports, 2016, 6, 39217.	1.6	3

#	Article	IF	Citations
163	Lack of Efficacy: When Opioids Do Not Achieve Analgesia from the Beginning of Treatment in Cancer Patients . Cancer Management and Research, 2019, Volume 11, 10337-10344.	0.9	3
164	Sequence and Gene-Specific Drugs. , 1992, , 5-11.		3
165	Biochemical studies on the ability of pentamethylmelamine to interact in vivo with DNA and proteins in a sensitive murine ovarian reticular cell sarcoma. Biochemical Pharmacology, 1984, 33, 2715-2722.	2.0	2
166	Extranodal Marginal Zone B-Cell Lymphoma Genotyping byAluâ€" Polymerase Chain Reaction. Leukemia and Lymphoma, 2000, 38, 605-610.	0.6	2
167	LKB1ness Dictates ERK Inhibitors Response in NSCLC. Journal of Thoracic Oncology, 2020, 15, e59.	0.5	2
168	Predicting the Role of DNA Polymerase Î² Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy. Journal of Clinical Medicine, 2020, 9, 2438.	1.0	2
169	DNA mirror groove-binding agents. Drugs of the Future, 2005, 30, 301.	0.0	2
170	Abstract 3739: Comparison of technologies forEGFRanalysis within a subset of a randomized clinical trial. , 2017, , .		2
171	Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?-An update incorporating the DELTA trial data. Journal of Thoracic Disease, 2015, 7, 224-6.	0.6	2
172	Central side effects of pentamethylmelamine: Biochemical and behavioural studies. Biochemical Pharmacology, 1984, 33, 4011-4015.	2.0	1
173	The inhibition of supercoiling activity of DNA gyrase from Micrococcus luteus caused by rufloxacin (MF 934) and MF 961. Journal of Antimicrobial Chemotherapy, 1991, 27, 687-689.	1.3	1
174	Role of Cetuximab in the Treatment of Patients With NSCLC: Are We Throwing Out the Baby With the Bath Water?. Journal of Clinical Oncology, 2010, 28, e467-e467.	0.8	1
175	Correlation between clinical outcomes of patients treated within the tailor trial and next-generation sequencing (NGS) results: Analysis of genes associated to KRAS mutations. Annals of Oncology, 2017, 28, ii61.	0.6	1
176	KRAS Targeting and Resistance: Anticipating the Expectable. Journal of Thoracic Oncology, 2021, 16, 1239-1241.	0.5	1
177	Abstract 2652: Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas. , 2015, , .		1
178	Abstract B77: KRAS mutational status impact progression-free survival of patients treated with platinum-based chemotherapy in NSCLC.. , 2011, , .		1
179	The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response. Blood, 2014, 124, 1782-1782.	0.6	1
180	Abstract 508: DNA repair status in a patient derived ovarian cancer xenobank. , 2017, , .		1

#	Article	IF	Citations
181	DNA interstrand cross-links induced by cis-dichlorodiammine platinum in ovarian cancer cells growing in primary culture. Biochemical Pharmacology, 1988, 37, 1835-1836.	2.0	0
182	âˆ†Np73beta induces caveolin-1 in human non-small cell lung cancer cell line H1299. Tumor Biology, 2016, 37, 2015-2021.	0.8	0
183	P2.02-065 RanBP9 is a Novel Prognostic and Predictive Biomarker for NSCLC and Affects Cellular Response to Cisplatin and PARP Inhibitors. Journal of Thoracic Oncology, 2017, 12, S2123-S2124.	0.5	0
184	Itâ€™s Got Too Greedy. New Therapeutic Options for Metabolic[ally] Addicted NSCLC?. Cancers, 2020, 12, 3223.	1.7	0
185	Single-arm, open label prospective trial to assess prediction of the role ofÂERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy. ESMO Open, 2021, 6, 100034.	2.0	0
186	miR-17 Epigenetic Modulation of LKB1 Expression in Tumor Cells Uncovers a New Group of Patients With Poor-Prognosis NSCLC. Journal of Thoracic Oncology, 2021, 16, e68-e70.	0.5	0
187	Abstract 792: DRAGO (KIAA0247), a new p53-regulated antioncogene.. , 2013, , .		0
188	Abstract 4406: Role of KRAS in modulating the metabolomic profile and the response of NSCLC cells to PI3K/mTOR and AMPK interfering agents. , 2014, , .		0
189	Abstract 2766: Inhibition of Chk1 and Wee1 as a new therapeutic approach in Mantle Cell Lymphoma. , 2014, , .		0
190	Abstract 3760: Role of epithelial to mesenchymal transition in response to cisplatin in patient-derived ovarian carcinomas. , 2014, , .		0
191	Abstract 803: A vertical combination strategy hitting multiple steps along the MAPK cascade: Molecular mechanisms of action and putative genetic determinants of synergism. , 2014, , .		0
192	Abstract A54: Studies on the molecular mechanisms responsible for cisplatin resistance associated to KRAS G12C mutation in NSCLC. , 2014, , .		0
193	Abstract 3500: Combinations of ARQ087 with chemotherapeutic agents are safe and show a striking antitumor activity in different xenograft models. , 2015, , .		0
194	Abstract 1654: The small molecule YK-4-279 shows anti-lymphoma activity in pre-clinical models. , 2015, , .		0
195	Abstract 226: PI3K pathway inhibition induces a different metabolic response in NSCLC cells harboring WT and G12C mutant KRAS. , 2016, , .		0
196	Abstract 380: The dual PI3K/MTOR inhibitor PQR309 is active in mature B cell lymphoma cell lines bearing resistance to the PI3K-delta inhibitor idelalisib and specific gene expression features. , 2016, , .		0
197	Co-existance of KRAS and LKB1 mutation as predictor of resistance to Erlotinib: Customized next-generation sequencing (NGS) of TAILOR trial.. Journal of Clinical Oncology, 2017, 35, e20631-e20631.	0.8	0
198	Abstract 2352: Effect of inhibition of cell cycle versus transcription cyclin-dependent kinases (CDKs) in ovarian cancer cells. , 2017, , .		0

#	Article	IF	Citations
199	Abstract 174: Preclinical activity of new liposomal formulation of doxorubicin (TLD-1). , 2017, , .		0
200	Abstract 760: Detection of EGFR T790M mutation by ddPCR in untreated NSCLC patients: Correlation with clinical outcome. , 2017, , .		0
201	Abstract A112: RanBP9 protects cells from genotoxic stress and increased expression is predictive of worse response to platinum in NSCLC patients. , 2018, , .		0
202	Abstract LB-245: Multiple DNA-damage response pathways are modulated by RANBP9 protein in NSCLC. , 2018, , .		0
203	Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell lines. American Journal of Cancer Research, 2020, 10, 4488-4497.	1.4	0